Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib

Go Top